Protocols

Biotech billionaire backs a food allergy/nutrition startup; Editas recruits a CMO

Swiss biotech billionaire Ernesto Bertarelli is putting some of his cash into a new Silicon Valley startup that will look to help prevent food allergies before they can take hold. His Gurnet Point Capital is taking the lead on a $13 million Series A for Before Brands.

Cambridge, MA-based Editas has recruited Gerald Cox as its new CMO. He was most recently VP of Rare Disease Clinical Development at Sanofi Genzyme and has spent more than 20 years as a practicing clinical geneticist at Boston Children’s Hospital.

Lilly has agreed to buy out Boehringer Ingelheim’s portfolio of animal vaccines, paying $885 million for the package deal as it beefs up its work in animal-related products.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 29,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Head of DMPK, Director
Magenta Therapeutics Cambridge, MA
Research Scientist - Disease Biology & Cellular Pharmacology
Recursion Pharmaceuticals Salt Lake City
Sr/Medical Director, Medical Affairs
A Rare Disease Biotech New Brunswick, NJ
VP, Pharmacovigilance
Aeglea BioTherapeutics Austin, TX
Process Scientist/Lead
Tmunity Therapeutics Philadelphia, PA

Visit Endpoints Careers ->